Source-grounded facts extracted from Theriva Biologics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.
“On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.”
Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).
“On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)”
Theriva Biologics, Inc. announced a restructuring with charges of approximately $520,000 affecting global Company workforce (approximately seven employees or 32% of the current global Company workforce).
“its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and”
Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.